7.75
0.22 (2.92%)
| Previous Close | 7.53 |
| Open | 7.58 |
| Volume | 724,614 |
| Avg. Volume (3M) | 1,026,786 |
| Market Cap | 516,151,616 |
| Price / Sales | 2.66 |
| Price / Book | 1.44 |
| 52 Weeks Range | |
| Earnings Date | 27 Apr 2026 |
| Profit Margin | -0.64% |
| Operating Margin (TTM) | -13.00% |
| Diluted EPS (TTM) | -0.010 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 3.55% |
| Current Ratio (MRQ) | 28.71 |
| Operating Cash Flow (TTM) | 7.81 M |
| Levered Free Cash Flow (TTM) | 4.40 M |
| Return on Assets (TTM) | -2.74% |
| Return on Equity (TTM) | -0.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Fulcrum Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.50 |
|
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.82% |
| % Held by Institutions | 96.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| First Turn Management, Llc | 31 Dec 2025 | 1,892,683 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Feb 2026 | Announcement | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |